Asakawa H, Kobayashi T, Komoike Y, Maruyama H, Nakano Y, Tamaki Y, Matsuzawa Y, Monden M
Second Department of Internal Medicine, Osaka University Medical School, Japan.
Anticancer Res. 1997 Jul-Aug;17(4A):2757-62.
The prognosis of anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC) is very poor because of their resistance to chemotherapy.
We retrospectively evaluated the response to chemotherapy of 14 patients with ATC and examined the in vitro chemosensitivity of primary cultures of one ATC and five PDTCs from six recent patients.
As assessed at one month after treatment, one patient had a partial remission (PR), 3 had no change (NC), and the other 10 progressed (PD). The mean survival of all 14 patients was 3.4 months (PD; 2.3 months, PR or NC; 6 months). Five of the tumors (one ATC and four PDTCs) were resistant to all drugs examined: adriamycin, cisplatin, cyclophosphamide, etoposide, and carboplatin; cells from one PDTC were sensitive to adriamycin alone. Although five patients had administration of anti-cancer agents, none showed a response to chemotherapy.
most ATCs and PDTCs are very resistant to anti-cancer agents. In vitro chemosensitivity testing may prevent the administration of ineffective chemotherapy.
间变性甲状腺癌（ATC）和低分化甲状腺癌（PDTC）由于对化疗耐药，其预后非常差。
我们回顾性评估了14例ATC患者对化疗的反应，并检测了来自最近6例患者的1例ATC和5例PDTC原代培养物的体外化疗敏感性。
治疗1个月后评估，1例患者部分缓解（PR），3例无变化（NC），其他10例进展（PD）。14例患者的平均生存期为3.4个月（PD；2.3个月，PR或NC；6个月）。5个肿瘤（1例ATC和4例PDTC）对所有检测药物耐药：阿霉素、顺铂、环磷酰胺、依托泊苷和卡铂；1例PDTC的细胞仅对阿霉素敏感。尽管5例患者接受了抗癌药物治疗，但均未显示对化疗有反应。
大多数ATC和PDTC对抗癌药物非常耐药。体外化疗敏感性检测可能避免给予无效的化疗。
